Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06126-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Xue Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Flow Cytometry, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Polymerase Chain Reaction. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties, Sanming Project of Medicine in Shenzhen, Shenzhen Key Medical Discipline Construction Fund.
Abstract (Originalsprache)
Blinatumomab has shown to improve survival outcomes in B-cell acute lymphoblastic leukemia (B-ALL) patients with measurable residual disease (MRD) detected by multiparametric flow cytometry (MFC). However, data on blinatumomab clearing MRD with high sensitivity remain scarce. This study evaluates the effectiveness of blinatumomab in eradicating low levels of MRD, as detected by droplet digital PCR (ddPCR) but undetectable by MFC, in children with B-ALL. Patients (n = 9) whose MRD was undetectable by MFC but detectable by ddPCR after chemotherapy and followed by blinatumomab consolidation were included retrospectively. After the administration of blinatumomab, 5 out of 9 patients (55.56%) successfully achieved undetectable levels of ddPCR-MRD. Notably, among the 4 patients with BCR::ABL1 gene-positive acute lymphoblastic leukemia (ALL), only one achieved gene negativity. Starting from the initiation of blinatumomab treatment, with a median follow-up of 12 months, all patients remained in complete remission. Our study was the first to demonstrate that blinatumomab could further eradicate ddPCR MRD after patients achieve MFC-MRD undetectable status in B-ALL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
- Department of Hematology and Oncology, Shenzhen Children's Hospital of China Medical University, Shenzhen, China.
- Department of Hematology and Oncology, Children Hospital of Chongqing Medical University, Chongqing, China.
- National Clinical Research Center for Child Health and Disorders, Chongqing, China.
- Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
- Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China. 18938690228@163.com.
Förderung
- Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties
- Sanming Project of Medicine in Shenzhen
- Shenzhen Key Medical Discipline Construction Fund
- Shenzhen High-level Hospital Construction Fund
- Guangdong High-level Hospital Construction Fund
Zitieren
APA
Tang, X., Liu, S., Hu, Y., Chen, F., Wang, L., Li, T., Liu, Y., Zhou, G., Liu, S., Liu, S., Wen, F., Wang, Y., Mai, H., & Xiao, J. (2024). Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry. Annals of Hematology. https://doi.org/10.1007/s00277-024-06126-8
Vancouver
Tang X, Liu S, Hu Y, Chen F, Wang L, Li T, et al. Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry. Annals of Hematology. 2024. doi:10.1007/s00277-024-06126-8
BibTeX
@article{Tang2024,
author = {Tang, Xue and Liu, Siyu and Hu, Yanni and Chen, Fen and Wang, Lulu and Li, Tonghui and Liu, Yi and Zhou, Guichi and Liu, Shilin and Liu, Sixi and Wen, Feiqiu and Wang, Ying and Mai, Huirong and Xiao, Jianwen},
title = {Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06126-8}
}
EUVIMED